Readoutin 14d
TransThera Sciences (Nanjing), Inc. — Tinengotinib 8 mg
Phase 3 primary completion: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Cholangiocarcinoma